// App-Quantinova.ai

4554 : Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

Researchers

Presenter

  • Chun Loo Gan

Principal Investigators

  • Andrew Lachlan Schmidt

  • Thomas Powles

  • Ben Tran

  • Luis A Meza

  • Chris Labaki

  • Jae-Lyun Lee

  • Lori Wood

  • Julia Shapiro

  • D. Scott Ernst

  • Anil Kapoor

  • Christina M. Canil

  • Takeshi Yuasa

  • Rana R. McKay

  • Benoit Beuselinck

  • Frede Donskov

  • Shaan Dudani

  • Toni K. Choueiri

  • Daniel Yick Chin Heng

Medical Centers

  • Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada

  • Canada.

  • Univ of Calgary, Calgary, Canada

  • Liz Plummer Cancer Centre, Cairns and Hinterland Hospital and Health Service, Cairns, QLD, Australia

  • Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free National Health Service Trust,, London, United Kingdom

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • City of Hope Comprehensive Cancer Center, Monrovia, CA

  • Dana Farber Cancer Institute - (Individuals), Boston, MA

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Dalhousie University, Halifax, NS, CA

  • Western Hospital, Melbourne, Australia

  • Division of Medical Oncology, Department of Oncology, London Regional Cancer Program, London Health Sciences Centre and University of Western Ontario,, London, ON, Canada

  • McMaster Institute of Urology, St Joseph's Healthcare, Hamilton, ON

  • The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada

  • Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

  • University of California, San Diego, Moores Cancer Center, La Jolla, CA

  • Leuven Cancer Institute, Universitaire Ziekenhuizen, Leuven, Belgium

  • Aarhus University Hospital, Aarhus, Denmark

  • Ottawa Hospital Cancer Center, University of Ottawa, Ottawa, ON, Canada

  • Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, MA

Locations

  • Canada

  • Australia

  • United Kingdom

  • United States

  • Japan

  • Belgium

  • Denmark

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

  • Techniclone TNT

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved